Roche’s group sales in the first 6 months of 2022 increased by 5% compared to the same period of the previous year and amounted to CHF 32.3 billion, thanks to the work carried out by Pharmaceuticals and Diagnostics divisions. Roche shared the information that 3 percent growth was recorded in the Pharmaceutical Department and 11 percent in the Diagnostics Department.
Roche, one of the world’s leading biotechnology companies and one of the leading companies in personalized diagnosis and treatment, announced its financial results for the first half of 2022.
Demonstrating its financial success in the first half of 2022 with its activities in the healthcare sector, Roche’s group sales increased by 5 percent to CHF 32.3 billion. According to data, Roche Pharmaceutical grew by 3 percent to approximately CHF 22.3 billion, driven by strong demand for the new treatments and Roche Diagnostics sales increased by 11 percent to CHF 9.9 billion.
“We aim to maintain growth throughout the year”
Evaluating the half-year financial results of 2022, Roche Group CEO Severin Schwan said, “We achieved good results in the first half of the year, thanks to the continued strong demand for our diagnostics base business and our new medicines to treat hemophilia, cancer and neurological disorders. Thanks to the ongoing renewal of our portfolio, we continue to grow despite biosimilars, whose impact declined further as expected. Based on our current assessment, we confirm the outlook for the full year.”
Roche continues to support the fight against COVID-19 variants
While Roche supports the fight against COVID-19 and its variants globally during the pandemic, it’s predicted that COVID-19 diagnosis and treatment sales will decrease by approximately CHF 2 billion to approximately CHF 5 billion in the upcoming period and expects sales losses from biosimilars this year to be around CHF 2.5 billion. Despite these anticipated changes, group sales are expected to grow in the high single-digit range.
Global growth goes on with continued strong demand for treatment solutions
The financial data of Roche Pharmaceuticals Division reached CHF 22.3 billion with a 3 percent growth compared to the first six months of the previous year. Strong demand for Roche’s treatments for diseases such as hemophilia, multiple sclerosis, cancer and spinal muscular atrophy played a significant role in this growth.
Continuing strong growth in diagnostics across all regions
According to the announced half-term financial report, the growth of the Roche Diagnostics Division was determined by 11 percent, while its sales reached the level of CHF 9.9 billion. Strong growth of 6 percent was recorded in the division’s core business area, including all regions. While Roche’s COVID-19 tests reached a sales volume of CHF 2.5 billion in the first six months of last year, it was recorded that the sales volume increased to CHF 3.1 billion in the same period of this year. The company predicts that demand for COVID-19 tests will decrease in the third quarter of the year.
Outlook for 2022
Roche’s sales are expected to continue to grow steadily in low single digits in the second half of 2022, while core earnings per share are targeted to grow in the low to mid-single digit range (at constant exchange rates), including the increased impact of the 2021 share buyback. The company also hopes to increase its dividend in CHF.
